Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece

被引：3

作者：

Boukovinas, Ioannis ^{[1
]}

Kotsakis, Athanasios ^{[2
]}

Androulakis, Nikolaos ^{[3
]}

Aravantinos, Gerasimos ^{[4
]}

Michalaki, Vasiliki ^{[5
]}

Christodoulou, Christos ^{[6
]}

Avgerinos, Antonios ^{[7
]}

Papandreou, Christos ^{[8
,9
]}

Sidiropoulou, Vasiliki ^{[10
]}

Kousidou, Olga ^{[10
]}

Kosmidis, Paris ^{[11
]}

机构：

[1] Bioclin Thessaloniki, Oncol Dept, Thessaloniki, Greece

[2] Gen Univ Hosp Heraklion, Oncol Clin, Iraklion, Greece

[3] Pananio Venizelio Gen Hosp Heraklion, Internal Med Dept, Oncol Unit, Iraklion, Greece

[4] Agioi Anargyroi Gen Hosp, Internal Med Oncol Clin 2, Athens, Greece

[5] Aretaeio Gen Univ Hosp, Oncol Dept, Athens, Greece

[6] Metropolitan Hosp, Med Oncol Unit 2, Piraeus, Greece

[7] Papanikolaou Gen Hosp Thessaloniki, Dept Gastroenterol, Thessaloniki, Greece

[8] Papageorgiou Gen Hosp Thessaloniki, Dept Internal Med Oncol, Thessaloniki, Greece

[9] Gen Univ Hosp Larissa, Oncol Unit, Larisa, Greece

[10] Novartis Hellas, Med Dept, 12th Km Natl Rd 1, Athens, Greece

[11] Hygeia Hosp, Med Oncol Dept 2, Athens, Greece

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 01期

关键词：

Gastrointestinal stromal tumour; GIST; imatinib; real-world; survival; safety; ADJUVANT IMATINIB; GUIDELINES; RESECTION; MESYLATE;

D O I：

10.21873/anticanres.13971

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The purpose of the Imadje study was to confirm the efficacy and safety of imatinib, following resection of kit-positive gastrointestinal stromal tumour (GIST), in the adjuvant setting in the Greek population. Patients and Methods: A total of 34 adult patients already receiving imatinib were enrolled. Recurrence-free (RFS) and overall survival, as well as time to treatment failure and safety were assessed. Results: Overall survival could not be estimated in the present study, as no death occurred. Overall, 91.2% of patients were recurrence-free at 36 months, while the median time to treatment failure was 35 months. No new or unexpected safety findings were observed. Mutation analysis in 14 patients showed that the most frequent mutations were located in KIT exon 11 (64.3%) and exon 9 (28.6%). Univariate analysis showed that only surgical resection with a margin classification of R0 was associated with better RFS. Conclusion: Adjuvant treatment with imatinib for 3 years

引用

页码：435 / 441

页数：7

共 50 条

[31] A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
Yin, Yuan
Xiang, Jin
Tang, Sumin
Chen, Jiaju
Yu, Qin
Zhang, Bo
MEDICINE, 2016, 95 (49) : e5488
[32] Imatinib mesilate for the treatment of gastrointestinal stromal tumour
Cassier, Philippe A.
Dufresne, Armelle
Arifi, Sarnia
El Sayadi, Hiba
Labidi, Inticlar
Ray-Coquard, Isabelle
Tabone, Severine
Meeus, Pierre
Ranchere, Dominique
Sunyach, Marie-Pierre
Decouvelaere, Anne-Valerie
Alberti, Laurent
Blay, Jean-Yves
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) : 1211 - 1222
[33] Neoadjuvant Imatinib in Gastrointestinal Stromal Tumors (GIST): The First Analysis of a Mexican Population
Guzman, Rafael Medrano
Lara, Xavier Lopez
Rivera, Atl Simon Arias
Rios, Luis. E. Garcia
Chaoul, Moises Brener
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
[34] Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib
Wilkinson, M. J.
Fitzgerald, J. E. F.
Strauss, D. C.
Hayes, A. J.
Thomas, J. M.
Messiou, C.
Fisher, C.
Benson, C.
Tekkis, P. P.
Judson, I.
BRITISH JOURNAL OF SURGERY, 2015, 102 (08) : 965 - 971
[35] Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
Hohenberger, P.
Ronellenfitsch, U.
Oladeji, O.
Pink, D.
Stroebel, P.
Wardelmann, E.
Reichardt, P.
BRITISH JOURNAL OF SURGERY, 2010, 97 (12) : 1854 - 1859
[36] The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy
Guerin, Annie
Sasane, Medha
Gauthier, Genevieve
Keir, Christopher H.
Zhdavana, Maryia
Wu, Eric Q.
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 241 - 248
[37] Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST)
Kurteva G.P.
Kurtev P.F.
memo - Magazine of European Medical Oncology, 2010, 3 (2) : 49 - 52
[38] An unusual presentation of a Gastrointestinal stromal tumour (GIST)
John S.K.P.
Basu S.
Lawrance R.J.
Davies N.
World Journal of Surgical Oncology, 5 (1)
[39] Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec®, Gleevec™)
Joensuu, H
MEDIZINISCHE KLINIK, 2002, 97 : 28 - 30
[40] Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain
Rubio, J.
Marcos-Gragera, R.
Ortiz, M. R.
Miro, J.
Vilardell, L.
Girones, J.
Hernandez-Yague, X.
Codina-Cazador, A.
Bernado, L.
Izquierdo, A.
Colomer, R.
EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) : 144 - 148

← 1 2 3 4 5 →